The PCSK9 Inhibitors: A Lipid-lowering Therapy to Treat Atherosclerotic Cardiovascular Diseases

protein.These markers are known to contribute to the development and severity of atherosclerosis.PCSK9 levels were independently associated with white blood cell count, lymphocyte and neutrophil counts, fibrinogen, and highsensitivity C-reactive protein, even in patients not receiving lipid-lowering therapy.These findings suggest that PCSK9 may be involved in vascular inflammation, suggesting that PCSK9 inhibitors may have anti-inflammatory benefits in CAD, although further research is needed to determine the